| 发明名称 | Crystalline anti-hTNFalpha antibodies | ||
| 摘要 | The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions. | ||
| 申请公布号 | US8772458(B2) | 申请公布日期 | 2014.07.08 |
| 申请号 | US201313774706 | 申请日期 | 2013.02.22 |
| 申请人 | AbbVie Biotechnology Ltd | 发明人 | Koenigsdorfer Anette;Gottschalk Stefan;Krause Hans-Juergen;Winter Gerhard;Borhani David W.;Fraunhofer Wolfgang |
| 分类号 | C07K16/00 | 主分类号 | C07K16/00 |
| 代理机构 | McCarter & English, LLP | 代理人 | McCarter & English, LLP ;Cowles Cristin H.;Kim Soo-Hwa |
| 主权项 | 1. A method for treating a TNFalpha-related disorder in a subject in need thereof, said method comprising the step of administering to the subject an effective amount of anti-hTNFalpha antibody crystals, wherein the antibody is an isolated human IgG antibody comprising two heavy chains each with a molecular weight of about 50 kpa, a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, and wherein the crystals have a needle-like morphology with a length 1 of about 2-500 μm and an 1/d ratio of about 3 to 30. | ||
| 地址 | Hamilton BM | ||